Evidence map›Paper›PMID 33986486›Full record

ArticleEuropean journal of clinical nutrition2022

Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT).

David L Chan, Stephen J Clarke, Alexander Engel, Connie I Diakos, Nick Pavlakis, Paul J Roach, Dale L Bailey, Judith Bauer, Merran Findlay

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?International journal of molecular sciences · 2024
    Article
  10. Sarcopenia and Neuroendocrine Neoplasms.Current oncology reports · 2024
    Review
  11. Article
  12. Article
  13. New Insights in PRRT: Lessons From 2021.Frontiers in endocrinology · 2022
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David L ChanDepartment of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia. david.chan@sydney.edu.au.ORCID http://orcid.org/0000-0002-7773-3144
Stephen J ClarkeDepartment of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
Alexander EngelSydney Vital Translational Cancer Research Centre, Sydney, NSW, Australia.
Connie I DiakosDepartment of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
Nick PavlakisDepartment of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
Paul J RoachDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia.
Dale L BaileySydney Vital Translational Cancer Research Centre, Sydney, NSW, Australia.
Judith BauerSchool of Human Movement and Nutrition Sciences, University of Queensland, St Lucia, QLD, Australia.
Merran FindlayCancer Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.ORCID http://orcid.org/0000-0001-6964-1533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesNeuroendocrine neoplasms (NEN) may predispose patients to malnutrition. CT-defined sarcopenia and myosteatosis are common in other tumour types and recognized adverse prognostic factors. However, the prevalence and prognostic impact of sarcopenia and myosteatosis remain undetermined in NEN patients to date.

methodsA retrospective study of NEN patients treated with peptide receptor radionuclide therapy (PRRT) at a tertiary institution from 2012 to 2017. Patients with PET/CT imaging at baseline and follow-up were included. The L3 slice of the co-localizing CT was analysed using the Alberta Protocol. Skeletal muscle cross-sectional area and muscle attenuation were measured and compared with pre-defined cut-offs. The primary endpoint was the prevalence of sarcopenia and myosteatosis according to previously published cut-offs.

resultsFourty-nine patients (median age 64 (range 26-80) years) were included. The most common primary sites of tumour were the small bowel (51%) and pancreas (26%). Baseline sarcopenia was prevalent in 67% of patients and myosteatosis in 71%. Forty-five percent of patients gained weight over the course of PRRT. The presence of baseline sarcopenia was not associated with progression-free survival (20.8 mo vs. 20.7 mo, HR 0.86, p = 0.70) nor overall survival. Similarly, baseline myosteatosis (PFS 19.5 mo vs. 20.8 mo, HR 0.77, p = 0.47) was not significantly associated with survival outcomes. The mean (SD) age of those with myosteatosis was 60.8 ± 11.6 years compared to 49.7 ± 12.7 years for those without (p = 0.003).

conclusionsBody composition analysis is feasible using routinely acquired PET/CT data for patients with NEN. CT-defined sarcopenia and myosteatosis are prevalent in NEN patients, although myosteatosis is more common with increasing age. These findings were not associated with worsened overall or progression-free survival in the current study.

Indexed as

NeoplasmsSarcopeniaAdultAgedAged, 80 and overHumansMiddle AgedMuscle, SkeletalPositron Emission Tomography Computed TomographyPrognosisRadioisotopesReceptors, PeptideRetrospective StudiesTomography, X-Ray ComputedRadioisotopesReceptors, Peptide

Identifiers

PMID33986486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.